The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Moiseev S.V.

Kafedra terapii i profbolezneĭ Pervogo moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, MGU im. M.V. Lomonosova

Capacities of somatostatin analogues to treat castration-resistant prostate cancer

Authors:

Moiseev S.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2012;1(1): 77‑82

Read: 51224 times

Download PDF (RU)
Contact the author
Table of contents

CAPACITIES OF SOMATOSTATIN ANALOGUES TO TREAT CASTRATION-RESISTANT PROSTATE CANCER
CAPACITIES OF SOMATOSTATIN ANALOGUES TO TREAT CASTRATION-RESISTANT PROSTATE CANCER

To cite this article:

Moiseev SV. Capacities of somatostatin analogues to treat castration-resistant prostate cancer. P.A. Herzen Journal of Oncology. 2012;1(1):77‑82. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cost of supportive cancer care in the Russian Fede­ration. Part 2. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):63-73
Transfusion therapy of the XIX century — the begi­nning of the formation of pare­nteral nutrition for surgical patients. Piro­gov Russian Journal of Surgery. 2025;(3):156-163
The effect of the iron III poly­saccharide complex use on the cyto­kines, natriuretic peptide and erythropoietin levels in patients with chro­nic heart failure acco­mpanied with anemia. Russian Journal of Preventive Medi­cine. 2025;(3):80-86
Iron supplements and erythropoiesis-stimulating agents in inte­nsive care of postpartum hemo­rrhage: a Bayesian network meta-analysis. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):59-67
What we have to change in the treatment of ST-segment elevation myocardial infa­rction?. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):183-190
Differential diagnosis of anemia in ulce­rative coli­tis: a clinical case. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):115-120
Erythrocyte indi­ces — markers for the diagnosis of blood iron defi­ciency in donors. Russian Journal of Preventive Medi­cine. 2025;(6):88-91
A review of the recent clinical studies on the treatment of patients with the chro­nic kidney disease et adva­nced stages. Russian Journal of Preventive Medi­cine. 2025;(8):110-114
Resu­lts of comprehensive geriatric evaluation in outpatients over 65 years old depe­nding on the presence of anemia. Suba­nalysis of the EVKA­LIPT study. Russian Journal of Preventive Medi­cine. 2025;(9):101-111
Abstract:

Anemia is common in malignant diseases, particularly in most patients receiving chemotherapy. The paper discusses the causes of anemia in cancer patients, its treatments, including packed red blood cell transfusion, erythropoietic stimulants, and intravenous iron preparations.

Keywords:

malignant tumors
anemia
hemotransfusion
erythropoietic stimulants
iron preparations

Authors:

Moiseev S.V.

Kafedra terapii i profbolezneĭ Pervogo moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, MGU im. M.V. Lomonosova

Close metadata

References:

  1. Knight K., Wade S., Balducci L. Prevalence and outcomes of anaemia in cancer: a systematic review of the literature. Am. J. Med. 2004; 116 (suppl. 7A): 11S-26S.
  2. Tas F., Eralp Y., Basaran M., Sakar B., Alici S., Argon A. et al. Anaemia in oncology practice: relation to diseases and their therapies. Am. J. Clin. Oncol. 2004; 2 (suppl. 1): 11-26.
  3. Ludwig H., van Belle S., Barrett-Lee P., Birgegård G., Bokemeyer C., Gascón P. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer. 2004; 40 (15): 2293-306.
  4. Varlotto J., Stevenson M. Anemia, tumor hypoxemia, and the cancer patient. Int. J. Radiat. Oncol. Biol. Phys. 2005; 63 (1): 25-36.
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cancer- and chemotherapy-induced Anemia. Version 2.2012 (R). www.NCCN.org.
  6. Miller Y., Bachowski G., Benjamin R. et al. Practice Guidelines for Blood Transfusion: A compilation from recent peer-reviewed literature. 2-nd ed. American National Red Cross; 2007.
  7. Wiesen A., Hospenthal D., Byrd J., Glass K.L., Howard R.S., Diehl L.F. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann. Intern. Med. 1994; 121: 278-30.
  8. Aapro M., Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008; 13 (suppl. 3): 33-6.
  9. Hebert P., Wells G., Blajchman M., Marshall J., Martin C., Pagliarello G. et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N. Engl. J. Med. 1999; 340: 409-17.
  10. Novik A.V. Anemiya i metabolicheskie rasstroistva u onkologicheskikh bol'nykh. Prakticheskaya onkologiya. 2009; 10 (3): 131-40.
  11. Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist. 2011; 16 (suppl. 3): 12-8.
  12. Churchhousea A., Mathewsa T., McBridea O., Dunning J. Does blood transfusion increase the chance of recurrence in patients undergoing surgery for lung cancer? Interactive Cardiovasc. Thorac. Surg. 2012; 14: 85-90.
  13. Bohlius J., Tonia T., Schwarzer G. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. Acta Haematol. 2011; 125: 55-67.
  14. Bohlius J., Wilson J., Seidenfeld J., Piper M., Schwarzer G., Sandercock J. et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. 2006; 98: 708-14.
  15. Bennett C., Silver S., Djulbegovic B., Samaras A.T., Blau C.A., Gleason K.J. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J.A.M.A. 2008; 299: 914-24.
  16. Tonelli M., Hemmelgarn B., Reiman T., Manns B., Reaume M.N., Lloyd A. et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a metaanalysis. Can. Med. Assoc. J. 2009; 180: E62-71.
  17. Ludwig H., Crawford J., Osterborg A., Vansteenkiste J., Henry D.H., Fleishman A. et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebocontrolled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J. Clin. Oncol. 2009; 27: 2838-47.
  18. Glaspy J., Crawford J., Vansteenkiste J., Henry D., Rao S., Bowers P. et al. Erythropoiesisstimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer. 2010; 102: 301-15.
  19. Milovanov Yu.S., Milovanova L.Yu., Kozlovskaya L.V. Nefrogennaya anemiya: patogenez, prognosticheskoe znachenie, printsipy lecheniya. Klinicheskaya nefrologiya. 2010; 6: 7-18.
  20. Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J. et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009; 373: 1532-42.
  21. Food and Drug Administration. Epoetin alfa label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103234Orig 1s5166_103234Orig1s5266lbl.pdf.
  22. Schrijvers D., de Samblanx H., Roila F., on behalf of the ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann. Oncol. 2010; 21 (suppl. 5): v244-7.
  23. Aapro M., Osterborg A., Gasco P., Ludwig H., Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann. Oncol. 2012. doi:10.1093/annonc/mds112.
  24. Beale A., Penney M., Allison M. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal. Dis. 2005; 7: 398-402.
  25. Ludwig H., Muldur E., Endler G. et al. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica. 2011; 96: abstr. 982.
  26. Anker S., Comin C., Filippatos G., Willenheimer R., Dickstein K., Drexler H. et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 2009; 361: 2436-48.
  27. Moiseev S.V. Zheleza karboksimal'tozat (Ferinzhekt) - novyi vnutrivennyi preparat dlya lecheniya zhelezodefitsitnoi anemii. Klinicheskaya farmakologiya i terapiya. 2012; 21 (2): 48-53.
  28. Coyne D. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int. 2011; 80 (3): 240-4.
  29. Dvoretskii L.I. Zhelezodefitsitnaya anemiya v praktike terapevta. Russkii meditsinskii zhurnal. 2009; 23: 1517-21.
  30. Grasso P. Sarcoma after intramuscular iron injection. Br. Med. J. 1973; 2: 667.
  31. Auerbach M., Ballard H., Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007; 369: 1502-4.
  32. Geisser R. The pharmacology and safety profile of ferric carboxymaltose (Ferinject®): structure/reactivity relationships of iron preparations. Port. J. Nephrol. Hypert. 2009; 23 (1): 11-6.
  33. Hedenus M., Birgegård G. The role of iron supplementation during epoietin treatment for cancer-relatedanemia. Med. Oncol. 2009; 26 (1): 105-15.
  34. Auerbach M., Ballard H., Trout J., McIlwain M., Ackerman A., Bahrain H. et al. Intravenous iron optimizes the response to recombinant human erythropoietinin cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 2004; 22 (7): 1301-7.
  35. Henry D., Auerbach M., Tchekmedyiand S., Laufmane L. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007; 12 (2): 231-42.
  36. Petrelli F., Borgonovo K., Cabiddu M., Lonati V., Barni S. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J. Cancer Res. Clin. Oncol. 2012; 138 (2): 179-87.
  37. Hedenus M., Nasman P., Liwing J. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. J. Clin. Pharm. Ther. 2008; 33: 365-74.
  38. Auerbach M., Ballard H., Trout J., McIlwain M., Ackerman A., Bahrain H. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 2004; 22: 1301-7.
  39. Bailie G., Horl W., Verhof J. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. Drug Res. 2011; 61: 267-75.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.